Status:
COMPLETED
Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Brief Summary
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.
Eligibility Criteria
Inclusion
- 2 or more risk factors (according to NCEP ATP III guideline)
- Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.
Exclusion
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
- Previous enrolment or randomisation of treatment in the present study.
- Participation in a clinical study during the last 90 days.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
8000 Patients enrolled
Trial Details
Trial ID
NCT00687492
Start Date
May 1 2008
End Date
December 1 2008
Last Update
December 2 2010
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Hong Kong, Hong Kong, China
2
Research Site
Semarang, Central Java, Indonesia
3
Research Site
Jakarta, DKI Jakarta, Indonesia
4
Research Site
Sidoarjo, East Java, Indonesia